Giulio Francolini1,2, Barbara Alicja Jereczek-Fossa3,4, Vanessa Di Cataldo1,2, Gabriele Simontacchi5, Giulia Marvaso4, Maria Alessia Zerella4, Piercarlo Gentile6, Federico Bianciardi6, Sara Allegretta6, Beatrice Detti5, Laura Masi7, Monica Lo Russo5, Lorenzo Livi8. 1. Radiation Oncology Unit, University of Florence, Florence, Italy. 2. CyberKnife Center, L'Istituto Fiorentino di Cura e Assistenza (IFCA), Florence, Italy. 3. Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 4. Division of Radiotherapy, European Institute of Oncology (IEO), L'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy. 5. Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 6. University of Pittsburgh Medical Center (UPMC) San Pietro Fatebenefratelli (FBF), Rome, Italy. 7. Department of Medical Physics and Radiation Oncology, IFCA, Florence, Italy. 8. Department of Biomedical, Experimental, and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Abstract
OBJECTIVE: To assess the safety and effectiveness of stereotactic salvage radiotherapy (SSRT) in RT-naïve patients affected by macroscopic prostate bed recurrence. PATIENTS AND METHODS: Consecutive patients treated for prostate bed macroscopic recurrence in three different Italian institutes were reviewed. Patients were treated with SSRT, with a total dose of 30-40 Gy in five fractions, the mean pre-SSRT PSA level was 2.3 ng/mL. Two different PSA thresholds were defined and biochemical recurrence-free survival (BCRFS) was reported, in order to better express outcome: BCRFS1 (a PSA level increase of >10% compared to the pre-SSRT value) and BCRFS2 (a PSA level increase of >0.2 ng/mL for patients with a PSA nadir of <0.2 ng/mL or two consecutive PSA level increases of >25% compared to nadir in patients with a PSA nadir of <0.2 ng/mL). RESULTS: In all, 90 patients were treated, with a mean (range) follow-up of 21.2 (2-64) months, and 17 of these patients (19%) had concomitant androgen-deprivation therapy (ADT) during SSRT. Complete biochemical response, defined as a PSA nadir of <0.2 ng/mL, was obtained in 39 of the 90 patients (43.3%). Considering BCRFS1, 25 patients (27.8%) had BCR, with an actuarial median BCRFS1 time of 36.4 months. For BCRFS2, BCR was reported in 32 patients (35.5%), with an actuarial median BCRFS2 time of 24.3 months. There was no Grade >2 toxicity. CONCLUSIONS: SSRT was found to yield significant biochemical control and allowed ADT delay despite adverse features.
OBJECTIVE: To assess the safety and effectiveness of stereotactic salvage radiotherapy (SSRT) in RT-naïve patients affected by macroscopic prostate bed recurrence. PATIENTS AND METHODS: Consecutive patients treated for prostate bed macroscopic recurrence in three different Italian institutes were reviewed. Patients were treated with SSRT, with a total dose of 30-40 Gy in five fractions, the mean pre-SSRT PSA level was 2.3 ng/mL. Two different PSA thresholds were defined and biochemical recurrence-free survival (BCRFS) was reported, in order to better express outcome: BCRFS1 (a PSA level increase of >10% compared to the pre-SSRT value) and BCRFS2 (a PSA level increase of >0.2 ng/mL for patients with a PSA nadir of <0.2 ng/mL or two consecutive PSA level increases of >25% compared to nadir in patients with a PSA nadir of <0.2 ng/mL). RESULTS: In all, 90 patients were treated, with a mean (range) follow-up of 21.2 (2-64) months, and 17 of these patients (19%) had concomitant androgen-deprivation therapy (ADT) during SSRT. Complete biochemical response, defined as a PSA nadir of <0.2 ng/mL, was obtained in 39 of the 90 patients (43.3%). Considering BCRFS1, 25 patients (27.8%) had BCR, with an actuarial median BCRFS1 time of 36.4 months. For BCRFS2, BCR was reported in 32 patients (35.5%), with an actuarial median BCRFS2 time of 24.3 months. There was no Grade >2 toxicity. CONCLUSIONS: SSRT was found to yield significant biochemical control and allowed ADT delay despite adverse features.
Authors: Christina Schröder; Hongjian Tang; Paul Windisch; Daniel Rudolf Zwahlen; André Buchali; Erwin Vu; Tilman Bostel; Tanja Sprave; Thomas Zilli; Vedang Murthy; Robert Förster Journal: Cancers (Basel) Date: 2022-01-29 Impact factor: 6.639
Authors: Jörg Tamihardja; Leonie Zehner; Philipp E Hartrampf; Sinan Cirsi; Sonja Wegener; Andreas K Buck; Michael Flentje; Bülent Polat Journal: Cancers (Basel) Date: 2022-10-10 Impact factor: 6.575